Enhanced antitumor activity of combined megestrol acetate and arsenic trioxide treatment in liver cancer cells.

about

Enhanced antitumor activity of combined megestrol acetate and arsenic trioxide treatment in liver cancer cells.

Item

http://www.wikidata.org/entity/Q52629281

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Enhanced antitumor activity of ...... eatment in liver cancer cells.

@en

Enhanced antitumor activity of ...... eatment in liver cancer cells.

@nl

type

Item

label

Enhanced antitumor activity of ...... eatment in liver cancer cells.

@en

Enhanced antitumor activity of ...... eatment in liver cancer cells.

@nl

prefLabel

Enhanced antitumor activity of ...... eatment in liver cancer cells.

@en

Enhanced antitumor activity of ...... eatment in liver cancer cells.

@nl

P1476

Enhanced antitumor activity of ...... eatment in liver cancer cells.

@en

P2093

Beibei Liu

http://www.w3.org/2001/XMLSchema#string

Geng Tian

http://www.w3.org/2001/XMLSchema#string

Xianhao Liu

http://www.w3.org/2001/XMLSchema#string

Xiaoshi Zhang

http://www.w3.org/2001/XMLSchema#string

Yan Xia

http://www.w3.org/2001/XMLSchema#string

P2860

Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace

Challenges of advanced hepatocellular carcinoma

Megestrol acetate: promises and pitfalls

An overview of megestrol acetate for the treatment of advanced breast cancer

Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors

Mitogen-activated protein kinases: specific messages from ubiquitous messengers

A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.

Phase i study evaluating the treatment of patients with hepatocellular carcinoma (HCC) with carbon ion radiotherapy: the PROMETHEUS-01 trial

The lethal phenotype of cancer: the molecular basis of death due to malignancy.

Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies.

P304

4047-4055

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/ETM.2018.5905

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-02-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29581752

http://www.w3.org/2001/XMLSchema#string

P932

5863599

http://www.w3.org/2001/XMLSchema#string